Eli Lilly and Company (NYSE:LLY) Shares Acquired by Capital Square LLC

Capital Square LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,074 shares of the company’s stock after acquiring an additional 14 shares during the quarter. Eli Lilly and Company accounts for approximately 2.3% of Capital Square LLC’s investment portfolio, making the stock its 4th largest position. Capital Square LLC’s holdings in Eli Lilly and Company were worth $3,986,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Highline Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after acquiring an additional 20 shares during the last quarter. FPC Investment Advisory Inc. boosted its position in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $58,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 9th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Citigroup lowered their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,012.00.

Eli Lilly and Company Trading Down 2.9 %

NYSE:LLY opened at $734.85 on Thursday. The company has a market capitalization of $696.76 billion, a P/E ratio of 62.75, a P/E/G ratio of 1.40 and a beta of 0.51. The stock’s 50 day moving average price is $830.10 and its 200 day moving average price is $820.95. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.